BRIEF-Positive Herizon-GEA-01 Phase 3 Results Support Ziihera As Her2-Targeted Agent-Of-Choice And Ziihera Combination Regimens As New Standard Of Care In First-Line Her2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma
Reuters
Nov 17, 2025
BRIEF-Positive Herizon-GEA-01 Phase 3 Results Support Ziihera As Her2-Targeted Agent-Of-Choice And Ziihera Combination Regimens As <a href="https://laohu8.com/S/NSE.AU">New Standard</a> Of Care In First-Line Her2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma
Nov 17 (Reuters) - Jazz Pharmaceuticals PLCJAZZ.O:
POSITIVE HERIZON-GEA-01 PHASE 3 RESULTS SUPPORT ZIIHERA® (ZANIDATAMAB-HRII) AS HER2-TARGETED AGENT-OF-CHOICE AND ZIIHERA COMBINATION REGIMENS AS NEW STANDARD OF CARE IN FIRST-LINE HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC GASTROESOPHAGEAL ADENOCARCINOMA
JAZZ PHARMACEUTICALS PLC: PLANS TO SUBMIT A SUPPLEMENTAL BLA FOR THIS INDICATION IN FIRST HALF OF 2026
Source text: nPn7Z9Jnca
Further company coverage: JAZZ.O
((Reuters.Briefs@thomsonreuters.com;))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.